Jan Nyman

6.5k total citations · 1 hit paper
107 papers, 4.3k citations indexed

About

Jan Nyman is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Jan Nyman has authored 107 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Pulmonary and Respiratory Medicine, 36 papers in Oncology and 33 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Jan Nyman's work include Lung Cancer Diagnosis and Treatment (32 papers), Lung Cancer Treatments and Mutations (26 papers) and Advanced Radiotherapy Techniques (23 papers). Jan Nyman is often cited by papers focused on Lung Cancer Diagnosis and Treatment (32 papers), Lung Cancer Treatments and Mutations (26 papers) and Advanced Radiotherapy Techniques (23 papers). Jan Nyman collaborates with scholars based in Sweden, Denmark and Norway. Jan Nyman's co-authors include Ingela Turesson, Karl-Axel Johansson, Signe Friesland, Erik Holmberg, Eva Hammerlid, Ingmar Lax, Rolf Lewensohn, N.G. Burnet, Anders Odén and Ewa Silander and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and The Lancet Oncology.

In The Last Decade

Jan Nyman

105 papers receiving 4.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Outcome in a Prospective Phase II Trial of Medically Inoperable Stage I Non–Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiotherapy

2009 653 citations Pia Baumann, Jan Nyman et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jan Nyman Sweden	33	2.5k	1.6k	1.5k	955	737	107	4.3k
Mary Feng United States	36	2.2k 0.9×	1.7k 1.1×	1.9k 1.3×	896 0.9×	1.1k 1.4×	108	5.2k
Giuseppe Sanguineti Italy	45	3.1k 1.2×	1.7k 1.1×	2.4k 1.7×	1.1k 1.2×	2.3k 3.1×	231	5.8k
Chaosu Hu China	36	1.8k 0.7×	1.1k 0.7×	888 0.6×	1.4k 1.4×	2.1k 2.8×	229	4.6k
Jesper Grau Eriksen Denmark	36	1.1k 0.4×	871 0.6×	647 0.4×	1.0k 1.1×	1.6k 2.2×	158	4.3k
Vincent Grégoire France	26	1.3k 0.5×	1.2k 0.7×	829 0.6×	1.1k 1.2×	2.7k 3.6×	85	4.2k
Frank Hoebers Netherlands	37	2.7k 1.1×	4.8k 3.1×	514 0.4×	1.5k 1.6×	1.5k 2.0×	147	7.5k
Walter Van den Bogaert Belgium	41	2.4k 1.0×	1.9k 1.2×	1.9k 1.3×	1.8k 1.9×	1.7k 2.3×	78	6.8k
Daniel M. Aebersold Switzerland	34	1.4k 0.5×	625 0.4×	609 0.4×	1.2k 1.3×	803 1.1×	225	4.6k
Yong Chan Ahn South Korea	40	3.3k 1.3×	1.1k 0.7×	712 0.5×	2.9k 3.0×	859 1.2×	282	6.9k
Vratislav Strnad Germany	30	1.2k 0.5×	1.1k 0.7×	1.4k 1.0×	859 0.9×	897 1.2×	161	3.9k

Countries citing papers authored by Jan Nyman

Since Specialization

Citations

This map shows the geographic impact of Jan Nyman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan Nyman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan Nyman more than expected).

Fields of papers citing papers by Jan Nyman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan Nyman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan Nyman. The network helps show where Jan Nyman may publish in the future.

Co-authorship network of co-authors of Jan Nyman

This figure shows the co-authorship network connecting the top 25 collaborators of Jan Nyman. A scholar is included among the top collaborators of Jan Nyman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan Nyman. Jan Nyman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gebre‐Medhin, Maria, Gabriel Adrian, Per Engström, et al.. (2025). Chemoradiation therapy With Cisplatin Versus Cetuximab in Patients With Locoregionally Advanced Head and Neck Squamous Cell Cancer—Mature Results of the ARTSCAN III Trial. International Journal of Radiation Oncology*Biology*Physics. 123(3). 681–690.

Grønberg, Bjørn Henning, Øystein Fløtten, Maria Moksnes Bjaanæs, et al.. (2025). High-Dose Versus Standard-Dose Twice-Daily Thoracic Radiotherapy in Limited-Stage SCLC: Final Survival Data, Long-Term Toxicity, and Relapse Patterns in a Randomized, Open-Label, Phase II Trial. Journal of Thoracic Oncology. 20(8). 1108–1119. 1 indexed citations

Bosæus, Ingvar, et al.. (2025). Malnutrition in patients with advanced head and neck cancer: Exploring the Global Leadership Initiative on Malnutrition (GLIM) criteria, energy balance and health-related quality of life. Clinical Nutrition ESPEN. 66. 332–342. 1 indexed citations

Silander, Ewa, Mogens Bove, Leif Johansson, et al.. (2024). A randomized study comparing the nutritional effects of radiotherapy with cetuximab versus cisplatin in patients with advanced head and neck cancer. Head & Neck. 46(4). 760–771. 3 indexed citations

Pettersson, Niclas, et al.. (2024). Assessment of radiation pneumonitis and predictive factors in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy. Acta Oncologica. 63. 791–797. 2 indexed citations

Wiel, Clotilde, Henrik Fagman, Levent M. Akyürek, et al.. (2022). KRAS Mutations Impact Clinical Outcome in Metastatic Non-Small Cell Lung Cancer. Cancers. 14(9). 2063–2063. 16 indexed citations

Nyman, Jan, et al.. (2022). Human cutaneous interfollicular melanocytes differentiate temporarily under genotoxic stress. iScience. 25(10). 105238–105238. 5 indexed citations

Gebre‐Medhin, Maria, Eva Brun, Per Engström, et al.. (2020). ARTSCAN III: A Randomized Phase III Study Comparing Chemoradiotherapy With Cisplatin Versus Cetuximab in Patients With Locoregionally Advanced Head and Neck Squamous Cell Cancer. Journal of Clinical Oncology. 39(1). 38–47. 98 indexed citations

Abel, Edvard, Ewa Silander, Jan Nyman, Thomas Björk‐Eriksson, & Eva Hammerlid. (2019). Long-Term Aspects of Quality of Life in Head and Neck Cancer Patients Treated With Intensity Modulated Radiation Therapy: A 5-Year Longitudinal Follow-up and Comparison with a Normal Population Cohort. Advances in Radiation Oncology. 5(1). 101–110. 23 indexed citations

10.

Lindberg, Karin, Per Bergström, Odd Terje Brustugun, et al.. (2017). OA24.05 The Nordic HILUS-Trial - First Report of a Phase II Trial of SBRT of Centrally Located Lung Tumors. Journal of Thoracic Oncology. 12(1). S340–S340. 38 indexed citations

11.

Hallqvist, Andreas, Bengt Bergman, & Jan Nyman. (2012). Health related quality of life in locally advanced NSCLC treated with high dose radiotherapy and concurrent chemotherapy or cetuximab – Pooled results from two prospective clinical trials. Radiotherapy and Oncology. 104(1). 39–44. 24 indexed citations

12.

Wennberg, Berit, Pia Baumann, Giovanna Gagliardi, et al.. (2011). NTCP modelling of lung toxicity after SBRT comparing the universal survival curve and the linear quadratic model for fractionation correction. Acta Oncologica. 50(4). 518–527. 27 indexed citations

13.

Främling, Kary, et al.. (2010). Sharing Building Information with Smart-M3. 3. 347–357. 1 indexed citations

14.

Nyman, Jan, Andreas Hallqvist, Ola Brodin, et al.. (2009). Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: a phase II study from the Swedish Lung Cancer Study Group. Journal of Thoracic Oncology. 4(9). 373–373. 1 indexed citations

15.

Pettersson, Niclas, Jan Nyman, & Karl-Axel Johansson. (2009). Radiation-induced rib fractures after hypofractionated stereotactic body radiation therapy of non-small cell lung cancer: A dose– and volume–response analysis. Radiotherapy and Oncology. 91(3). 360–368. 137 indexed citations

16.

Nyman, Jan, Kary Främling, & Vincent Michel. (2008). GATHERING PRODUCT DATA FROM SMART PRODUCTS. International Conference on Enterprise Information Systems. 252–257. 6 indexed citations

17.

Nyman, Jan, Signe Friesland, Andreas Hallqvist, et al.. (2008). How to improve loco-regional control in stages IIIa–b NSCLC?. Lung Cancer. 65(1). 62–67. 23 indexed citations

18.

Nyman, Jan, et al.. (2005). Stereotactic hypofractionated radiotherapy for stage I non-small cell lung cancer—Mature results for medically inoperable patients. Lung Cancer. 51(1). 97–103. 196 indexed citations

19.

Hopewell, J. W., Jan Nyman, & Ingela Turesson. (2003). Time factor for acute tissue reactions following fractionated irradiation: a balance between repopulation and enhanced radiosensitivity. International Journal of Radiation Biology. 79(7). 513–524. 45 indexed citations

20.

Nyman, Jan & Ingela Turesson. (1995). Does the interval between fractions matter in the range of 4–8 h in radiotherapy? A study of acute and late human skin reactions. Radiotherapy and Oncology. 34(3). 171–178. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact